Zevra Therapeutics, Inc. (ZVRA) — SEC Filings
Zevra Therapeutics, Inc. (ZVRA) — 49 SEC filings. Latest: 10-Q (May 6, 2026). Includes 28 8-K, 7 10-Q, 5 DEFA14A.
View Zevra Therapeutics, Inc. on SEC EDGAR
Overview
Zevra Therapeutics, Inc. (ZVRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 17, 2025: On December 11, 2025, Zevra Therapeutics, Inc. announced changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans for key executives. Specific detail
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 44 neutral, 1 mixed. The dominant filing sentiment for Zevra Therapeutics, Inc. is neutral.
Filing Type Overview
Zevra Therapeutics, Inc. (ZVRA) has filed 7 10-Q, 28 8-K, 5 DEFA14A, 2 10-K, 3 SC 13G, 2 SC 13G/A, 1 DEF 14A, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of ZVRA's 39 recent filings, 3 were flagged as high-risk, 12 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $72.345M |
| Net Income | $71.064M |
| Cash Position | $54.439M |
| Total Assets | $270.116M |
| Total Debt | $61.310M |
Key Executives
- Neil F. McFarlane
- Adrian W. Quartel
- R. LaDuane Clifton
- Joshua Schafer
- Dr. Michael L. Smith
- Dr. David M. Reif
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like Zevra Therapeutics focus on developing and commercializing treatments for rare diseases, a niche with potentially high unmet needs but also smaller patient populations. The competitive landscape involves other specialty pharma companies and larger pharmaceutical firms with broader portfolios and greater resources.
Top Tags
financials (8) · filing (7) · corporate-governance (7) · 8-K (6) · 10-Q (5) · financial-condition (5) · pharmaceuticals (4) · regulatory-filing (4) · results-of-operations (4) · disclosure (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue, net | $26.063M | For three months ended September 30, 2025, up from $3.695M in 2024 |
| Net income | $71.064M | For nine months ended September 30, 2025, compared to a $69.772M net loss in 2024 |
| Gain on sale of PRV | $148.325M | Contributed to net income for nine months ended September 30, 2025 |
| Net loss | $0.544M | For three months ended September 30, 2025, improved from $33.225M loss in 2024 |
| Impairment of intangible assets | $58.710M | For nine months ended September 30, 2025 |
| Inventory obsolescence charge | $11.681M | For nine months ended September 30, 2025 |
| Cash and cash equivalents | $54.439M | As of September 30, 2025, up from $33.785M at December 31, 2024 |
| Total stockholders' equity | $133.165M | As of September 30, 2025, up from $39.666M at December 31, 2024 |
| Shares of common stock outstanding | 56,297,535 | As of November 3, 2025 |
| Net Loss | $17.3M | for Q2 2025, increased from $12.1M in Q2 2024 |
| Revenue | $1,528 | Revenue for the three months ended March 31, 2025, showing minimal sales. |
| Cash and Cash Equivalents | $54,679,363 | Liquidity position as of March 31, 2025. |
| Common Stock | 10,000,000 | Authorized shares of common stock. |
| Preferred Stock | 250,000,000 | Authorized shares of preferred stock. |
| Authorized Shares | 250,000,000 | Indicates the maximum number of shares the company can issue. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Zevra Therapeutics, Inc. (ZVRA)?
Zevra Therapeutics, Inc. has 49 recent SEC filings from Jan 2024 to May 2026, including 28 8-K, 7 10-Q, 5 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZVRA filings?
Across 49 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 44 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Zevra Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zevra Therapeutics, Inc. (ZVRA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zevra Therapeutics, Inc.?
Key financial highlights from Zevra Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ZVRA?
The investment thesis for ZVRA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zevra Therapeutics, Inc.?
Key executives identified across Zevra Therapeutics, Inc.'s filings include Neil F. McFarlane, Adrian W. Quartel, R. LaDuane Clifton, Joshua Schafer, Dr. Michael L. Smith and 1 others.
What are the main risk factors for Zevra Therapeutics, Inc. stock?
Of ZVRA's 39 assessed filings, 3 were flagged high-risk, 12 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from Zevra Therapeutics, Inc.?
Forward guidance and predictions for Zevra Therapeutics, Inc. are extracted from SEC filings as they are enriched.